The euro fell 0.5% to $1.0359, while the BoE cut pushed sterling down nearly 1% to below $1.24. Benchmark BoE rates are now ...

European shares climbed to new highs, buoyed by strong performances from AstraZeneca and miners. The Bank of England’s rate cut impacted the pound, while Wall Street remained flat ahead of Amazon’s ...

AstraZeneca (AZN) stock rises as its Q4 results which exceeded Street forecasts address concerns over its China investigation ...

LEXINGTON, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will ...

AstraZeneca has halted plans to build a £450 million vaccine plant in the UK due to decreased government support, prompting ...

Harvey Jones hails the brilliant long-term performance of the AstraZeneca share price, but wonders whether the FTSE 100's ...

AstraZeneca Plc reported better-than-expected profit and revenue in the fourth quarter and forecast further gains, helped by ...

Stock markets rose Thursday on easing trade tensions and thanks to some strong company earnings, analysts said.

Pharma giant AstraZeneca urged Britain to improve the environment for businesses in order to drive investment, days after it ...

Astrazeneca PLC (AZN) on Thursday reported fourth-quarter earnings of $1.5 billion. On a per-share basis, the Cambridge, Britain-based company said it had net income of 48 cents. Earnings, adjusted ...

(Alliance News) - AstraZeneca PLC on Thursday ended a strong year with better-than-expected fourth quarter earnings and said its pipeline would support further growth in 2025.

AstraZeneca has ended development of its oral factor D inhibitor vemircopan, triggering a $753 million impairment charge as ...